Intended for healthcare professionals


NEJM corrects its study on rofecoxib

BMJ 2006; 333 doi: (Published 29 June 2006) Cite this as: BMJ 2006;333:12
  1. Susan Mayor
  1. London

    An increase in cardiovascular events associated with the cyclooxygenase-2 inhibitor rofecoxib (Vioxx) occurred much earlier in the course of treatment than the original study reporting the problem had indicated, says a correction published online in the New England Journal of Medicine on 26 June (, doi: 10.1056/NEJMx06).

    The correction to the study of …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription